{"name":"Porteus, Matthew, MD","slug":"porteus-matthew-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Depleted Stem Cell Transplant","genericName":"Depleted Stem Cell Transplant","slug":"depleted-stem-cell-transplant","indication":"Other","status":"phase_1"},{"name":"T-allo10 cells addback","genericName":"T-allo10 cells addback","slug":"t-allo10-cells-addback","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Depleted Stem Cell Transplant","genericName":"Depleted Stem Cell Transplant","slug":"depleted-stem-cell-transplant","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"T-allo10 cells addback","genericName":"T-allo10 cells addback","slug":"t-allo10-cells-addback","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQaU9pZkdEY3BhNjdCQTFpNW5Kek9BblAxXzlJMDhzWEM3S1U3SXIzWjlFZWhzNURBM3d0akY0Wm0zZWxoeG5YRFFISlItQXBNRTBteFJaTGlIQU85eTNuZjJtcnlVVFhKYXBXMmdoSC01V2c1MjhJZ0tNUExzYldoV2lnamRud0RoZ1B1TjJzc0xTMHQ5UGstMHhR?oc=5","date":"2026-02-03","type":"pipeline","source":"PharmTech.com","summary":"Cellares Scales IDMO Model for Gene-Edited Stem Cell Therapies - PharmTech.com","headline":"Cellares Scales IDMO Model for Gene-Edited Stem Cell Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdmxCTXpzSjJWeVYteEgwWlNvdE9rTzZIWkFRRWp5Yjc2bnFzQ09URFVSWWltX0tqYjFodS1Vd3hpYWJUM0VmbTctaDcwMzYydjBpNDFvdDI1UE9NaERPcmRzUXplc204bFdmZTFNbFItU25jd3BUZThrbDRNVmpUVDRTWDFac0hHMzBCWWdiRmtaN3RQeW0tbmsxc2Z6a2N1Ul9xd0daMXc4RWM?oc=5","date":"2024-06-27","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"A Story of Perseverance: An Interview with Matthew Porteus - Genetic Engineering and Biotechnology News","headline":"A Story of Perseverance: An Interview with Matthew Porteus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQRHRKOW40MEMycFJvSjd6anVWTlRWSnFjT2VQR0FfUDRWUXlZLTJvTWRUQmU4N3ZzWkg2Qk1yUFJBSEIwckY4TS1rbW5xRmRQT0ZpRlhRdm9KZ1VEQVBxN3lkeGFyeHVVUUhHdWV1dFJvbm1Ub1M4eFlnc1NHRVQ4ODJLQ0pKSGxKVFlJSTNISGlFcjQ1SDd0YlU0X1g5dnBoc1d5bGpSV0stWXcwcXpxckZQZ0lGelhkWkVhdUJxbTZYczBQaWtvVWlYQmRuM3pMem05QkRYVEU?oc=5","date":"2023-12-11","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results - Genetic Engineering and Biotechnology News","headline":"A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQWDRmUk9fVGl5ekx3ZXVxbUlwcFVCaDAxUml2Mkx6THhNYUQ3U3VzSUoyY3VOSlJOeTNoY19VZmFXTVBXWXB4VGdGLV9uMXhIbzlnbUtaMlEyZzFGVFRnSzVVYnJ5R1hEeTJsMERmaFlhbHE0RnhSZjBiREtZNGktYUxzLWxKZlRNY2RCaVF3N3p5cjhiM3Z2ajEyU3VsRlhDZmMwX2N6RzAzVGdnV2NmeThtN0MybmYwMkg3U1pXeHRVYzQtc2xJ?oc=5","date":"2023-12-08","type":"deal","source":"Fierce Biotech","summary":"Graphite breaks apart, with founder inking deal for abandoned sickle cell prospect, gene-editing tech - Fierce Biotech","headline":"Graphite breaks apart, with founder inking deal for abandoned sickle cell prospect, gene-editing tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNVEZFekJHOHJYVm1kaG4tLXJxLXdOWFVVWUNTUVFzRF9HejBrOUZFOUF1bklZY1kwZTZmRmpZYkZTc2t6Z2YtUm5qdTBXTG1HVGpUZTJGZWtzenhsbmJ0elI1NXNOU1JOZW1zaDVldDlkRlI4T0dxdnZJTzVydnVla3ZDQ25rZDB0MVAteTl1eG5ESEIyQjN2UkJvOA?oc=5","date":"2023-03-13","type":"pipeline","source":"Technology Networks","summary":"Cell and Gene Therapy 2023 Symposium - Technology Networks","headline":"Cell and Gene Therapy 2023 Symposium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE42SzlzRGxqZkFKM3NDREFGZ2pVVzY3akxUYzl6LUVXd1ozQVJPYkFuaDlVVDBKb0xMUkpUN2wtTE9pM1VNdGpLbDZyMU9RaE1kaXVnRjhfQzJ4Qlo2a09J?oc=5","date":"2019-03-06","type":"pipeline","source":"NEJM","summary":"A New Class of Medicines through DNA Editing | NEJM - NEJM","headline":"A New Class of Medicines through DNA Editing | NEJM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9kNklrcmlIdU84aU9IR1Bfc3M3Y1Ftdi03MDBJTEtQX3JOb29aSFhCRk5UUEw1NzZmRWI3Zno2OVZ1RkN6ajhSdmFaVjdoWVot?oc=5","date":"2018-06-29","type":"pipeline","source":"Stanford Medicine","summary":"News & Media - Stanford Medicine","headline":"News & Media","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}